Literature DB >> 23412936

Utilization of hyperinsulinemia euglycemia and intravenous fat emulsion following poison center recommendations.

Michael A Darracq1, Stephen L Thornton, Han M Do, Dennis Bok, Richard F Clark, F Lee Cantrell.   

Abstract

Hyperinsulinemia euglycemia (HIE) and intravenous fat emulsion (IFE) may be beneficial in the treatment of calcium channel (CCB) and beta receptor (BB) antagonist toxicity. Many poison control centers (PCC) now recommend use. Healthcare providers may be unfamiliar with these treatments and may not institute them despite recommendations. We sought to determine how often HIE and IFE are recommended by a statewide PCC in CCB and BB toxicity, how often those recommendations are implemented, and whether a faxable information sheet increased adherence. All cases of CCB and BB exposure from January 2005-July 2011 where insulin or "other therapy" was coded were reviewed. Exclusion criteria included an incomplete PCC record, miscoding, and insulin administration as other than cardiovascular drug antidotal therapy. There were 215 CCB or BB exposures initially identified using the search criteria. HIE was recommended in 71 cases and started in one case prior to PCC recommendation. HIE was subsequently used in 30 cases after PCC recommendation (42 %). IFE was recommended by the PCC in 30 cases and implemented 10 times (33 %). In six cases, both HIE and IFE were implemented after recommendation. There was no statistical difference when recommendation was made via telephone or by faxable information sheet for HIE or IFE. HIE and IFE are two therapies that are potentially beneficial in the treatment of BB and CCB toxicity. Current national organization guidelines for use are limited. Exploration of reasons for not following recommendations and additional efforts to improve clinician education regarding HIE and IFE may be required to increase the utilization of these potentially lifesaving antidotes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23412936      PMCID: PMC3770986          DOI: 10.1007/s13181-013-0290-2

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  13 in total

1.  2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report.

Authors:  Alvin C Bronstein; Daniel A Spyker; Louis R Cantilena; Jody L Green; Barry H Rumack; Richard C Dart
Journal:  Clin Toxicol (Phila)       Date:  2011-12       Impact factor: 4.467

Review 2.  Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.

Authors:  Terry L Vanden Hoek; Laurie J Morrison; Michael Shuster; Michael Donnino; Elizabeth Sinz; Eric J Lavonas; Farida M Jeejeebhoy; Andrea Gabrielli
Journal:  Circulation       Date:  2010-11-02       Impact factor: 29.690

3.  Intravenous lipid emulsion in propranolol [corrected] overdose.

Authors:  P Dean; J P Ruddy; S Marshall
Journal:  Anaesthesia       Date:  2010-11       Impact factor: 6.955

4.  ACMT position statement: interim guidance for the use of lipid resuscitation therapy.

Authors: 
Journal:  J Med Toxicol       Date:  2011-03

Review 5.  High-dose insulin therapy in beta-blocker and calcium channel-blocker poisoning.

Authors:  Kristin M Engebretsen; Kathleen M Kaczmarek; Jenifer Morgan; Joel S Holger
Journal:  Clin Toxicol (Phila)       Date:  2011-04       Impact factor: 4.467

Review 6.  Intravenous lipid emulsion as antidote: a summary of published human experience.

Authors:  Grant Cave; Martyn Harvey; Andis Graudins
Journal:  Emerg Med Australas       Date:  2011-04-07       Impact factor: 2.151

7.  Intentional overdose with cardiac arrest treated with intravenous fat emulsion and high-dose insulin.

Authors:  Samuel J Stellpflug; Carson R Harris; Kristin M Engebretsen; Jon B Cole; Joel S Holger
Journal:  Clin Toxicol (Phila)       Date:  2010-03       Impact factor: 4.467

8.  Diltiazem poisoning treated with hyperinsulinemic euglycemia therapy and intravenous lipid emulsion.

Authors:  Virginie Montiel; Thierry Gougnard; Philippe Hantson
Journal:  Eur J Emerg Med       Date:  2011-04       Impact factor: 2.799

9.  Compliance with poison center fomepizole recommendations is suboptimal in cases of toxic alcohol poisoning.

Authors:  Mark B Mycyk; Carol DesLauriers; Jessica Metz; Brandon Wills; Suzan S Mazor
Journal:  Am J Ther       Date:  2006 Nov-Dec       Impact factor: 2.688

10.  Intravenous fat emulsion therapy for intentional sustained-release verapamil overdose.

Authors:  Amy C Young; Larissa I Velez; Kurt C Kleinschmidt
Journal:  Resuscitation       Date:  2009-03-17       Impact factor: 5.262

View more
  5 in total

1.  Tweet this #toxicology2.0.

Authors:  Navneet Cheema
Journal:  J Med Toxicol       Date:  2014-03

2.  Lipid rescue 911: Are poison centers recommending intravenous fat emulsion therapy for severe poisoning?

Authors:  Michael R Christian; Erin M Pallasch; Michael Wahl; Mark B Mycyk
Journal:  J Med Toxicol       Date:  2013-09

3.  Barriers and Facilitators of Intensivists' Adherence to Hyperinsulinemia-Euglycemia Therapy in the Treatment of Calcium Channel Blocker Poisoning.

Authors:  Eric Brassard; Patrick Archambault; Guillaume Lacombe; Maude St-Onge
Journal:  J Med Toxicol       Date:  2018-07-25

4.  Experts Consensus Recommendations for the Management of Calcium Channel Blocker Poisoning in Adults.

Authors:  Maude St-Onge; Kurt Anseeuw; Frank Lee Cantrell; Ian C Gilchrist; Philippe Hantson; Benoit Bailey; Valéry Lavergne; Sophie Gosselin; William Kerns; Martin Laliberté; Eric J Lavonas; David N Juurlink; John Muscedere; Chen-Chang Yang; Tasnim Sinuff; Michael Rieder; Bruno Mégarbane
Journal:  Crit Care Med       Date:  2017-03       Impact factor: 7.598

5.  Outcomes following calcium channel blocker exposures reported to a poison information center.

Authors:  Mikkel B Christensen; Kasper M Petersen; Søren Bøgevig; Salam Al-Gibouri; Espen Jimenez-Solem; Kim P Dalhoff; Tonny S Petersen; Jon T Andersen
Journal:  BMC Pharmacol Toxicol       Date:  2018-11-27       Impact factor: 2.483

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.